Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

Yi Ming Li · Li Hui Zhang · Xue Jun Li · Bin Zhang · Jia Ning Hou · Nan Wei Tong

Received: January 6, 2020 / Published online: March 26, 2020 © The Author(s) 2020

ABSTRACT

Introduction: Glucagon-like peptide (GLP)-1 receptor agonists are glucose-lowering agents associated with weight loss, cardiovascular benefits, and low hypoglycemic risk and are recommended by recent guidelines as first-line therapy for some patients with type 2 diabetes (T2D). This post hoc analysis of the AWARD-CHN1 study compared the efficacy and safety of once-weekly dulaglutide with glimepiride in oral antihyperglycemic medication (OAM)-naïve Chinese patients with T2D.

Methods: AWARD-CHN1 was a phase 3, double-blind study with 737 patients randomized 1:1:1 to once-weekly dulaglutide (1.5 or 0.75 mg) or glimepiride (1–3 mg/day). This is a post hoc analysis of AWARD-CHN1 based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the OAM-naïve Chinese population.

Results: There were 264 OAM-naïve Chinese patients included in this analysis (dulaglutide 1.5 mg, \( n = 87 \); dulaglutide 0.75 mg, \( n = 90 \); glimepiride, \( n = 87 \)). A greater glycated hemoglobin (HbA1c) reduction from baseline was observed with dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (\(-2.02\%\) and \(-1.84\%\) vs \(-1.37\%\), respectively; both \( P < 0.001 \)). Significantly more patients in dulaglutide 1.5 mg and 0.75 mg groups achieved HbA1c targets < 7.0% compared to glimepiride (86.2% and 81.1% vs 65.5%; \( P = 0.002 \) and \( P = 0.026 \), respectively). Beta cell function was significantly increased for dulaglutide groups compared to glimepiride. Mean body weight was significantly reduced for dulaglutide 1.5 mg and 0.75 mg compared to glimepiride (\(-1.40\ kg \) and \(-0.96\ kg \) vs \(+0.73\ kg \), respectively; both \( P < 0.001 \)).
Through 26 weeks, 7.9%, 4.2%, and 18.2% of patients reported hypoglycemia, and 40.4%, 23.2%, and 8.0% of patients reported at least one gastrointestinal treatment emergent adverse event, in dulaglutide 1.5 mg, 0.75 mg, and glimepiride groups, respectively.

**Conclusions:** In this post hoc analysis, dulaglutide was effective in reducing both HbA1c and weight with favorable tolerability and safety profile, which is consistent with results seen in larger international dulaglutide monotherapy studies.

**Trial Registration:** ClinicalTrials.gov NCT01644500.

**Keywords:** China; Dulaglutide; Glimepiride; Type 2 diabetes

**Key Summary Points**

**Why carry out this study?**

Current study is a post hoc analysis of AWARD-CHN1 and evaluates efficacy and safety of once-weekly monotherapy of dulaglutide (1.5 mg and 0.75 mg) in OAM-naïve Chinese patients with type 2 diabetes (T2D) in comparison to glimepiride.

**What was learned from the study?**

Both the dulaglutide doses (1.5 mg and 0.75 mg) demonstrated significant reduction in HbA1c levels, with higher proportions of patients achieving HbA1c < 7% and ≤ 6.5% and greater reduction in FBG and SMBG levels, and significantly improved beta cell function, with a substantially lower risk of hypoglycemia, compared with glimepiride.

The overall findings from the current post hoc analysis demonstrate the potential for once-weekly dulaglutide monotherapy as a treatment for OAM-naïve Chinese patients with T2D, consistent with larger, international dulaglutide monotherapy studies.

**INTRODUCTION**

China currently has the world’s largest population of patients with diabetes, and prevalence of the disease has increased from 0.67% in 1980 to an estimated 10.9% in 2013. With China’s estimated 35.7% prevalence of prediabetes in 2013, treatment and prevention of type 2 diabetes (T2D) is a major public health issue [1, 2]. T2D is a progressive disease characterized by insulin resistance and impaired beta cell function, with beta cell failure caused by the increasing demands associated with insulin resistance [3]. According to data in the UK Prospective Diabetes Study [4], and from a study on preservation of beta cell function [5], about 50–80% of beta cell function may have decreased by the time diabetes is diagnosed. Treatments targeting these aspects are therefore essential to manage T2D. Glucagon-like peptide (GLP)-1 receptor agonists which mimic the gluco-regulatory actions of GLP-1 and resist dipeptidyl peptidase (DPP)-4 degradation have demonstrated efficacy to reduce glycated hemoglobin (HbA1c) with unique pharmacological effects that include delayed gastric emptying, diminished appetite, and glucose-dependent enhanced insulin secretion. GLP-1 receptor agonists can also improve beta cell function, as assessed by homeostatic model assessment (HOMA)-B analysis and proinsulin-to-insulin ratio, and markedly improve first- and second-phase insulin responses, and are able to restore beta cell sensitivity to glucose [3]. Additionally, GLP-1 receptor agonists are effective glucose-lowering agents associated with weight loss, cardiovascular benefits, and low risk of hypoglycemia, providing advantages over sulfonylureas, which are associated with hypoglycemia and weight gain, but are still widely used across East Asia [6–8].

Dulaglutide is a long-acting, once-weekly human GLP-1 receptor agonist approved to treat T2D. The dulaglutide molecule consists of two identical disulfide-linked chains. Each of these chains contains an N-terminal GLP-1 analogue sequence covalently bonded to a modified human immunoglobulin G4 Fc fragment with a small peptide. Compared to native
human GLP-1, the GLP-1 analogue portion of
dulaglutide is 90% homologous. The analogue
portion also contains amino acid substitutions
designed to improve the dulaglutide clinical
profile, so that it resists degradation from DPP-
4, is more soluble, and is less likely to trigger an
immune response. Likewise, dulaglutide delays
absorption and decreases renal clearance, hence
making dulaglutide a more soluble formulation
with a prolonged half-life of approximately
5 days and convenient for once-weekly subcu-
taneous dose administration [9–11].

In phase 3 studies, dulaglutide has demon-
strated significant HbA1c reductions with both
fasting and postprandial glucose improvements
and weight loss [12–15]. The AWARD-CHN1
trial was the first to evaluate the efficacy and
safety of dulaglutide (0.75 and 1.5 mg) to treat
T2D in East-Asian patients with inadequate
glycemic control who were either oral antihy-
perglycemic medication (OAM)-naïve or on
OAM monotherapy. This 26-week, multina-
tional, double-blind, randomized, parallel-arm,
phase 3 trial randomized patients with T2D
1:1:1 to dulaglutide 1.5 mg, 0.75 mg, or glime-
piride (1–3 mg/day), and demonstrated that
both doses of dulaglutide had improved gly-
cemic control and a higher number of patients
who achieved target HbA1c levels compared to
those receiving glibenpiride.

Given the favorable risk–benefit profile for
GLP-1 receptor agonists, it has been given
increasing priority in diabetes treatment rec-
ommendations, with some guidelines suggest-
ing it should be first-line therapy [16]. This post
hoc analysis of AWARD-CHN1 investigates the
safety and efficacy of dulaglutide versus gliben-
piride in OAM-naïve Chinese patients.

METHODS

Ethics

The AWARD-CHN1 study (ClinicalTrials.gov
NCT01644500) protocol was reviewed and
approved by the institutional ethics committee
at each study center and was conducted in
accordance with the principles of the Declara-
tion of Helsinki [17], Good Clinical Practice
guidelines, and applicable laws and regulations.
Written informed consent was obtained from
each patient before participation.

Study Design and Patients

The AWARD-CHN1 study was a randomized,
double-blind, parallel-arm, active comparator,
phase 3 study conducted over 26 weeks in East-
Asian countries. The study design and eligibility
criteria have been described previously [15].
Patients with T2D aged 18 years or more who
were OAM-naïve (with HbA1c ≥ 7.0% and
≤ 10.5% at screening) or discontinued from
OAM monotherapy for at least 3 months before
screening (with HbA1c ≥ 6.5% and ≤ 10.0% at
screening) were included. Key exclusion criteria
were diagnosis of type 1 diabetes, prior treat-
ment with GLP-1 receptor agonists or GLP-1
analogues, ongoing treatment with DPP-4
inhibitors or thiazolidinediones, or current or
prior (within 3 months before visit 1) chronic
insulin treatment.

This post hoc analysis of AWARD-CHN1
only included Chinese OAM-naïve patients.

Study Treatment

Eligible patients were randomly assigned 1:1:1
according to a computer-generated random
sequence using an interactive voice response
system to receive once-weekly dulaglutide
(1.5 mg), once-weekly dulaglutide (0.75 mg), or
glibenpiride (1–3 mg/day). The randomization
was stratified by baseline HbA1c (visit 3).

Assessments

The primary efficacy endpoint analyzed in this
post hoc analysis was a comparison of the
change in HbA1c from baseline at week 26
among the two dulaglutide and the glibenpiride
treatment groups. Other efficacy measures ana-
yzed were the proportion of patients attaining
HbA1c levels < 7% or ≤ 6.5%, changes in fast-
ing blood glucose (FBG) profile, 7-point self-
monitored blood glucose (SMBG) profile, blood
glucose excursions, and calculations of the
updated version of homeostasis model
assessment (HOMA2) (computed using fasting blood glucose, insulin, and C-peptide concentrations) of beta cell function (HOMA2-%B). Safety and tolerability were evaluated throughout by the assessments of weight change, hypoglycemic episodes, and treatment-emergent adverse events (TEAEs).

**Statistical Analysis**

The primary efficacy analysis, change in HbA1c from baseline at 26 weeks, was conducted on a mixed-model repeat measurement analysis using the modified intention-to-treat analysis set, which included all randomized Chinese OAM-naïve patients who had a baseline HbA1c measurement and at least one post-baseline HbA1c measurement and received at least one dose of study drug. The HbA1c test results for visit 3 were used as the baseline HbA1c concentration for the purpose of statistical analyses. For secondary efficacy analysis, between-treatment differences (both dulaglutide doses versus glimepiride) in the percentages of patients with HbA1c < 7.0% or ≤ 6.5% at 26 weeks were analyzed using Fisher’s exact test. Safety analyses were conducted on an as-treated analysis set that included Chinese OAM-naïve patients who received at least one dose of study drug and were analyzed according to the treatment they received, regardless of their planned treatment. All tests of the treatment effect were conducted at a one-sided alpha level of 0.025, assuming no true difference between treatments. Two-sided 95% confidence intervals (CIs) were included in the presentation of the results.

**RESULTS**

A total of 264 patients were included in this post hoc analysis (dulaglutide 1.5 mg = 87; dulaglutide 0.75 mg = 90; glimepiride = 87). Demographics and baseline characteristics of OAM-naïve patients are described in Table 1. A total of 101 (38.3%) patients were female, the mean (SD) HbA1c was 8.13% (1.03), and the mean duration of T2D was 1.55 years. Baseline characteristics were similar in the three treatment groups.

| Table 1 Demographic and baseline characteristics of OAM-naïve Chinese patients |
|--------------------------------------|----------------|----------------|----------------|
| Variables | DU 1.5 mg (N = 87) | DU 0.75 mg (N = 90) | Glimepiride (N = 87) |
| Sex female, n (%) | 31 (35.6) | 32 (35.6) | 38 (43.7) |
| Age, years | 49.6 (11.1) | 52.4 (8.9) | 50.9 (9.7) |
| BMI, kg/m² | 25.6 (3.3) | 25.9 (3.3) | 25.3 (2.8) |
| Body weight, kg | 70.3 (10.5) | 71.9 (11.5) | 69.1 (10.1) |
| HbA1c, % | 8.11 (1.03) | 8.21 (1.05) | 8.07 (1.01) |
| Duration of diabetes, years | 1.5 (2.2) | 1.8 (2.5) | 1.4 (2.3) |

Unless indicated otherwise, data are presented as the mean (± SD)

BMI body mass index, DU dulaglutide, HbA1c glycated hemoglobin A1c, kg kilogram, kg/m² kilograms per square meter, N total number of patients in specified treatment, n number of patients in specified category, OAM oral antidiabetic medication, SD standard deviation

At week 26, the least-squares mean (standard error) (LSM [SE]) change from baseline in HbA1c was greater in the dulaglutide 1.5 mg (− 2.02% [0.09]) and dulaglutide 0.75 mg (− 1.84% [0.09]) treatment groups than in the glimepiride (− 1.37% [0.09]) treatment group. The LSM for the differences between each dose of dulaglutide versus glimepiride was − 0.65% (95% CI − 0.91, − 0.39) for dulaglutide 1.5 mg and − 0.47% (95% CI − 0.73, − 0.21) for dulaglutide 0.75 mg at week 26, P < 0.001 for both comparisons (Fig. 1). Overall, the HbA1c reduction was significantly greater with both doses of dulaglutide compared to glimepiride. Figure 2 shows LSM (SE) change in HbA1c by visit from baseline to week 26 in all treatment groups.

At week 26, significantly greater proportions of patients achieved a decrease in HbA1c level to < 7.0% in the dulaglutide 1.5 mg and 0.75 mg groups compared with the glimepiride group (86.2% vs 65.5%, P = 0.002 for dulaglutide 1.5 mg and 81.1% vs 65.5%, P = 0.026 for dulaglutide 0.75 mg). Similarly, a significantly greater proportion of patients achieved a
A reduction in HbA1c level to 6.5% in the dulaglutide 1.5 mg compared with the glimepiride group (71.3% vs 51.7%; \( P = 0.012 \)). The proportion of patients achieving an HbA1c level of \( \leq 6.5\% \) at week 26 was numerically greater in the dulaglutide 0.75 mg group than the...
glimepiride group (63.3% vs 51.7%; \( P = 0.130 \)) (Fig. 3).

The LSM (SE) change in FBG from baseline to week 26 was significantly greater (\( P < 0.01 \)) in the dulaglutide 1.5 mg group compared with the glimepiride group (\(-2.32\) mmol/L [0.17] vs \(-1.66\) mmol/L [0.17]; \( P = 0.007 \)). No statistically significant difference in the change from baseline in FBG at week 26 was observed between the dulaglutide 0.75 mg and glimepiride groups (\(-1.94\) mmol/L [0.17] vs \(-1.66\) mmol/L [0.17]; \( P = 0.242 \)) (Fig. 4).

At each time point, the mean blood glucose values on the 7-point SMBG profile at week 26 were lower compared with baseline in all treatment groups. At week 26, a greater reduction in the 7-point SMBG profile was observed for dulaglutide 1.5 mg compared with glimepiride at all time points. The reductions in 7-point SMBG were also greater with dulaglutide 0.75 mg compared to glimepiride at morning pre-meal, morning 2-h postprandial meal, midday 2-h postprandial meal, evening 2-h postprandial meal, and at bedtime assessments (Fig. 5).

Over the 26-week treatment period, patients in both dulaglutide groups experienced weight loss. Conversely, patients in the glimepiride group gained weight. At week 26, the LSM (SE) change from baseline in body weight for dulaglutide 1.5 mg, dulaglutide 0.75 mg, and glimepiride was \(-1.40\) (0.318) kg, \(-0.96\) (0.312) kg, and \(0.73\) (0.311) kg, respectively (Fig. 6).

At week 26, significant increases in insulin- and C-peptide-based HOMA2 for beta cell function were observed in comparisons between both dulaglutide groups with glimepiride (\( P < 0.001 \) for dulaglutide 1.5 mg vs glimepiride and \( P < 0.05 \) for dulaglutide 0.75 mg vs glimepiride) (Fig. 7).

A total of 65 patients experienced at least one gastrointestinal (GI) TEAE during the 26-week study period (36 [40.4%] in dulaglutide 1.5 mg, 22 [23.2%] in dulaglutide 0.75 mg, and 7 [8.0%] in the glimepiride group). The total, documented, and nocturnal hypoglycemia rates (per year) were greater in the glimepiride group compared with both dulaglutide groups (Fig. 8). No episodes of severe hypoglycemia were observed in any group during the 26-week treatment period. The most frequently reported GI TEAEs included diarrhea, nausea, and abdominal distension, with a higher incidence reported in the dulaglutide groups compared with glimepiride (Table 2).

**Fig. 3** Percentage of OAM-naïve Chinese patients achieving HbA1c targets at week 26. \( P \) value is based on Fisher’s exact test. *\( P < 0.05 \) for DU 1.5 mg vs glimepiride and DU 0.75 mg vs glimepiride. DU dulaglutide, HbA1c glycated hemoglobin A1c, OAM oral antidiabetic medication
DISCUSSION

This post hoc analysis of the AWARD-CHN1 study is the first analysis designed to demonstrate the efficacy and safety of both doses of dulaglutide (1.5 mg and 0.75 mg) in OAM-naïve Chinese patients with T2D compared to glimepiride. The results demonstrated that both doses of dulaglutide resulted in greater reduction in HbA1c levels compared to glimepiride. The improvements observed in other efficacy outcome measures (i.e., percentage of patients who attained HbA1c targets, and changes in FBG profile, 7-point
Fig. 6 Change in body weight from baseline to 26 weeks in Chinese patients with T2D who were OAM-naïve. ^aLSM difference (95% CI) of dulaglutide with glimepiride. LSM are based on mixed-model repeated measures analysis. ^P < 0.001 dulaglutide vs glimepiride. CI confidence interval, DU dulaglutide, LSM least-squares mean, OAM oral antidiabetic medication, SE standard error, T2D type 2 diabetes

Fig. 7 Change in beta cell function from baseline to 26 weeks in Chinese patients with T2D who were OAM-naïve. ^aLSM difference (95% CI) of dulaglutide with glimepiride based on ANCOVA model. ^P < 0.001 dulaglutide 1.5 mg vs glimepiride. ^**P < 0.05 dulaglutide 0.75 mg vs glimepiride in both insulin-based HOMA2-%B and C-peptide-based HOMA2-%B groups. CI confidence interval, HOMA2-%B updated homeostasis model assessment of beta cell function, LSM least-squares mean, N number of patients in the analyses population for the specified treatment group, OAM oral antidiabetic medication, SE standard error, T2D type 2 diabetes
SMBG profile, insulin sensitivity, and beta cell function were also more pronounced after treatment with dulaglutide (both doses), which is consistent with the results of an overall study [15] and Chinese population [18].

Furthermore, in the overall population study [15], the Chinese subgroup [18], and the current OAM-naïve Chinese group, there were significantly more patients attaining HbA1c < 7.0% in the dulaglutide 1.5 mg group than in the glimepiride group (74.1% vs 57.4%, P < 0.001 for the overall population [15]; 71.7% vs 57.5%, P = 0.005 for Chinese subgroup [18]; 86.2% vs 65.5% P = 0.002 for patients who were OAM-naïve). Moreover, in this post hoc analysis, compared to glimepiride, a significantly greater proportion of patients treated with dulaglutide (1.5 mg and 0.75 mg) reached a target HbA1c of < 7.0%, with greater reductions in body weight and hypoglycemia at week 26. The finding of the present post hoc analysis is consistent with the post hoc analysis of AWARD-CHN1 and AWARD-CHN2 evaluating composite endpoints, in which 40–48% of patients on dulaglutide 1.5 mg, 30–39% of patients on dulaglutide 0.75 mg, and 15–20% of patients treated with active comparators (glimepiride/insulin glargine) reached a target HbA1c of < 7.0%, without weight gain or hypoglycemia at week 26 [19].

The significantly pronounced reduction in HbA1c observed in OAM-naïve patients in the current analysis with both dulaglutide doses was consistent with previously reported findings in a study of OAM-naïve patients [20] and other AWARD studies in which patients received OAM therapy [12–14]. Potential explanations for the greater reductions in HbA1c can be attributed to the lower body mass index (BMI) in the Asian population. BMI is highly correlated with insulin sensitivity [20–23], and an enhanced glycemic response in patients with lower baseline BMI can be certainly achieved [22]. Additionally, treatment with GLP-1 receptor agonists appears to be particularly more effective in Asian patients, who tend to have a pathophysiology of insulin secretion, since GLP-1 receptor agonists stimulate insulin secretion in a glucose-dependent manner and inhibit the release of glucagon [24, 25]. Another possible reason for greater HbA1c reduction is that the current analysis was conducted in patients with T2D who had no previous OAM therapy [26–28], which is a well-established baseline factor positively associated with favorable HbA1c response to antidiabetic drugs in clinical research [29].
In the current analysis, treatment with dulaglutide was also associated with an increase in beta cell function as measured by HOMA2-%B. The increases of insulin-based and C-peptide-based HOMA2-%B were significantly greater for both dulaglutide 1.5 mg and 0.75 mg groups compared with the glimepiride group, and these findings were consistent with dulaglutide AWARD-3 study findings, in which changes with dulaglutide 1.5 mg and 0.75 mg were greater than those with metformin (both comparisons, \( P \leq 0.001 \)) [14]. The improvements in HOMA2-%B in the current analysis provide great insight into the glucose-lowering mechanism of dulaglutide specifically related to enhanced pancreatic beta cell function. The duration of the study was relatively short considering the chronic nature of T2D, hence these HOMA2-%B results should be interpreted prudently. In the long run, the rise in HOMA2-%B may not translate into long-term improvement in beta cell function, and in fact may reflect a GLP-1 receptor agonist-mediated increase in insulin secretion [30].

The safety profile of dulaglutide in the present analysis of OAM-naive patients is consistent with the overall study [15] and with previous data from AWARD studies [12–14] and other compounds in the GLP-1 receptor agonist class [31]. The most common drug-related adverse events reported in the present analysis were GI (e.g., diarrhea or nausea), which were transient and rarely led to treatment discontinuation. In this post hoc analysis, the incidence of hypoglycemia in both dulaglutide treatment groups was low and similar to previous AWARD studies [12, 13]. Additionally, the increase in pancreatic enzymes observed in the current analysis is consistent with results of earlier studies of dulaglutide [32] and the GLP-1 receptor agonist class of drugs [33]; no cases of pancreatitis were reported in any treatment groups in the current analysis. Both doses of dulaglutide showed significantly greater decreases in body weight compared with glimepiride at the end of the treatment period. The mechanisms of weight loss with GLP-1 receptor agonists are probably related to delayed gastric emptying and decreased food intake caused by increased satiety [34–36].

According to the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) 2019 diabetes management algorithm [37], GLP-1 receptor agonists are the second preferred choice of treatment as monotherapy in patients with HbA1c < 7.5% after metformin [37] and the preferred choice as dual therapy with metformin in patients with HbA1c ≥ 7.5%. However, in OAM-naive patients, the AACE guideline suggests that patients with HbA1c > 7.5% and patients who are not on any antihyperglycemic drug treatment should start

### Table 2 Gastrointestinal adverse events through 26 weeks in OAM-naive Chinese patients

|                          | DU 1.5 mg (N = 89) | DU 0.75 mg (N = 95) | Glimepiride (N = 88) |
|--------------------------|-------------------|-------------------|---------------------|
| At least 1 GI TEAE, n (%)| 36 (40.4)         | 22 (23.2)         | 7 (8.0)             |
| Patients with ≥ 2% GI TEAE in any group, n (%) |                  |                   |                     |
| Diarrhea                 | 20 (22.5)         | 10 (10.5)         | 3 (3.4)             |
| Nausea                   | 11 (12.4)         | 2 (2.1)           | 1 (1.1)             |
| Abdominal distention     | 6 (6.7)           | 4 (4.2)           | 1 (1.1)             |
| Vomiting                 | 4 (4.5)           | 0 (0.0)           | 0 (0.0)             |
| Constipation             | 3 (3.4)           | 1 (1.1)           | 0 (0.0)             |
| Abdominal pain upper     | 3 (3.4)           | 2 (2.1)           | 0 (0.0)             |
| Abdominal discomfort     | 2 (2.2)           | 2 (2.1)           | 3 (3.4)             |
| Abdominal pain           | 2 (2.2)           | 0 (0.0)           | 0 (0.0)             |
| Abdominal pain lower     | 2 (2.2)           | 1 (1.1)           | 0 (0.0)             |
| GI disorder              | 3 (3.4)           | 1 (1.1)           | 0 (0.0)             |

Data presented are for safety population

DU: dulaglutide, GI: gastrointestinal, N: total number of patients in specified treatment group, n: number of patients in specified category, OAM: oral antidiabetic medication, TEAE: treatment-emergent adverse event
initially on metformin plus another agent [38]. In addition, according to the European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) 2019 guidelines, GLP-1 receptor agonists are recommended in patients with T2D and atherosclerotic cardiovascular disease or very high/high cardiovascular risk, whether they are treatment-naïve or already on metformin [16]. Also, according to the standards of care for T2D in China (2016), T2D blood glucose control strategy and treatment options and recommendations of International Diabetes Federation, the American Diabetes Association, and National Institute for Health and Clinical Excellence suggest initiating dual therapy with metformin and insulin secretagogues such as dulaglutide in patients with newly diagnosed T2D who have HbA1c ≥ 7% above their glycemic target. Thus, the current post hoc analysis suggests that dulaglutide in OAM-naïve patients reiterates the current guideline recommendations [39].

Limitations

The 26-week treatment period is relatively short for the assessment of glycemic control considering the chronic nature of T2D in OAM-naïve Chinese patients. Eventually, long-term studies are needed to evaluate the durability of weight and glycemic reductions made in this study. This post hoc analysis focused mainly on OAM-naïve patients; therefore, the applicability of this treatment in patients who are already on OAM treatment should be evaluated.

CONCLUSIONS

In this 26-week post hoc analysis, both dulaglutide doses demonstrated a significant reduction in HbA1c levels, higher proportion of patients achieved HbA1c < 7% and ≤ 6.5%, greater reduction in FBG levels and SMBG levels, and significantly improved beta cell function with a substantially lower risk of hypoglycemia compared with glimepiride. These findings demonstrate the potential for once-weekly dulaglutide monotherapy as a treatment for OAM-naïve Chinese patients with T2D, consistent with larger, international dulaglutide monotherapy studies.

ACKNOWLEDGEMENTS

Funding. This study was funded and supported by Eli Lilly and Company, and the Rapid Service Fee was also indemnified by Eli Lilly and Company. All authors had full access to all study data and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Writing and Editorial Assistance. The authors would like to thank Amol Gujar and Pranesh Kulkarni from Syneos Health for medical writing and Angela C. Lorio and Dana Schamberger from Syneos Health for editorial support in the preparation of this manuscript, which was funded by Eli Lilly and Company. The authors would also like to thank Chuyue Zeng from Eli Lilly and Company for project management.

Authorship. All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions. All named authors contributed to the study design, data analysis, and interpretation, as well as the drafting, review, and editing of the manuscript.

Compliance with Ethics Guidelines. The AWARD-CHN1 study (ClinicalTrials.gov NCT01644500) protocol was reviewed and approved by institutional ethics committee at each study center and was conducted in accordance with the principles of the Declaration of Helsinki of 1964 and its later amendments, Good Clinical Practice guidelines, and applicable laws and regulations. Written informed consent was obtained from each patient before participation.
Disclosures. The authors Yi Ming Li, Li Hui Zhang, Xue Jun Li, and Nan Wei Tong have nothing to disclose. Bin Zhang and Jia Ning Hou report being employees of Eli Lilly and Company.

Data Availability. The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;27:2515–23.

2. Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67:3–11.

3. Vilbsøll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab. 2009;11:11–8.

4. UK Prospective Diabetes Study Group. UKPDS 16: overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.

5. DeFronzo R, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96:2354–66.

6. Htike ZZ, Zaccardi F, Chatterjee S, Khunti K, Davies MJ. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. Br J Diabetes. 2016;16:128–37.

7. Weng J, Ji L, Jia W. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32:442–58.

8. Lu JM. The role of glucagon-like peptide-1 receptor agonists in type 2 diabetes in Asia. Adv Ther. 2019;36(4):798–805.

9. Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125–36.

10. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–96.

11. Trulicity® (dulaglutide) for injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.

12. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–67.

13. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–58.

14. Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168–76.

15. Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab. 2018;20:2121–30.

16. Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:255–323.
17. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–6.

18. Shi LX, Liu XM, Shi YQ, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: post-hoc analyses of a randomized, double-blind, phase III study. J Diabetes Investig. 2019. https://doi.org/10.1111/jdi.13187.

19. Xiao X, Wang C, Lai X, et al. Achieving the composite end-point of glycated hemoglobin < 7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: a post hoc analysis. J Diabetes Investig. 2019. https://doi.org/10.1111/jdi.13187.

20. Grunberger G, Chang A, Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29(10):1260–7.

21. Cheng YH, Tsao YC, Tzeng IS, et al. Body mass index and waist circumference are better predictors of insulin resistance than total body fat percentage in middle-aged and elderly Taiwanese. Medicine (Baltimore). 2017;96:e8126.

22. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–9.

23. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6.

24. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily lixisenatide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17:974–83.

25. Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019;21(2):234–43.

26. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448–60.

27. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glimepiride monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26:101–22.

28. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252–8.

29. Shi YQ, Zhang B, Wu H. Efficacy by baseline BMI with once weekly dulaglutide in Chinese T2DM patients. Diabetes. 2019. https://doi.org/10.2337/db19-2313-pub.

30. Mathieu C, Del Prato S, Botros FT, et al. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. Diabetes Obes Metab. 2018;20(8):2023–8.

31. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.

32. Terauchi Y, Satoh Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61(10):949–59.

33. Murphy CF, le Roux CW. Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events? Ann Transl Med. 2018;6(10):186.

34. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.

35. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913.

36. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

37. AACE/ACE comprehensive type 2 diabetes management algorithm. 2019. https://www.aace.com/pdfs/diabetes/AACE_2019_Diabetes_Algorithm_FINAL_ES.pdf. Accessed 01 Aug 2019.

38. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical
Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21:1–87.

39. Weng J, Ji L, Jia W, et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev. 2016;32(5):442–58.